Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: Results of a randomized multicenter trial

Journal of Hepatology

Volumn 30, Issue 5, 1999, Pages 788-793

  Andreone, Pietro ^a   Gramenzi, Annagiulia ^a   Cursaro, Carmela ^a   Sbolli, Giorgio ^b   Fiorino, Sirio ^a   Giammarino, Loriana Di ^a   Miniero, Rita ^c   D'Errico, Antonia ^a   Gasbarrini, Giovanni ^d   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale di Piacenza   (Italy)

^c Laboratorio Centralizzato   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hepatitis C; Interferon ; Ribavirin

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0033001317     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80130-5     Document Type: Article

References (29)

1. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dyonisos study. Hepatology. 20:1994;1442-1449.
2. Alter MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis. 15:1995;5-14.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1509-1511.
4. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
5. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;897-903.
6. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 337:1991;1058-1061.
7. Camps J, Garcia N, Riwzu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol. 19:1993;408-412.
8. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sönnerborg A, Weiland O for the Swedish Study Group . Randomised, doubleblind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
9. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 26:1997;961-966.
10. Lee CH, Cheng C, Wang J, Lumeng L. Identification of hepatitis C viruses with a nonconserved sequence of the 5′ untranslated region. J Clin Microbiol. 30:1992;1602-1604.
11. Kwok S, Higuchi R. Avoiding false-positives with polymerase chain reaction. Nature. 339:1989;237-238.
12. Lee J-H, Roth WK, Zeuzem S. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J Hepatol. 26:1997;1001-1009.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
14. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol. 23:(Suppl. 2):1995;13-16.
15. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol. 23:(Suppl 2):1995;17-21.
16. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-α combination therapy vs interferon-α alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat. 4:1997;185-191.
17. Sostegni R, Ghisetti V, Pittaluga F, Marchiano G, Rocca G, Borghesio E, et al. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology. 28:1998;341-346.
18. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol. 28:1996;505-511.
19. Marcellin P, Boyer N, Pouteau M, Benhamou P, Erlinger S. Retreatment with interferon-α of chronic hepatitis C virus infection. Lancet. 344:1994;690-691.
20. Bonkosky HL, Clifford BD, Sith LJ, Allan C, Banner B. High dose interferon-α2b for retreatment of non-responders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci. 41:1996;149-154.
21. Reichard O, Yun ZB, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during and after oral treatments with ribavirin for chronic hepatitis C. J Med Virol. 41:1993;99-102.
22. Di Bisceglie AM, Krawcynski K, Brazzeal D, Hoofnagle JH. Hepatitis C viral antigen in the liver: effect of antiviral therapy. Gastroenterology. 105:1993;858-862.
23. Koskinas J, Tibbs C, Saleh MG, Pereira LM, McFarlane IG, Williams R. Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon non-responsive patients. J Med Virol. 45:1995;29-34.
24. Gonzales-Peralta RP, Liu WZ, Davis GL, Qian KP, Lau JYN. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-α and ribavirin therapy. J Viral Hepat. 4:1997;99-106.
25. 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother. 25:1984;53-57.
26. Zeuzem S, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology. 28:1998;245-252.
27. Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-α J Viral Hepat. 2:1995;91-96.
28. Di Bisceglie AM, Vacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol. 21:1994;1109-1112.
29. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of Ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology. 105:1993;507-512.